Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 4/20 | 0.47 |
| ▸ | CSF1R | P07333 | 4/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642054 | 0.86 | NPSR1 (0.46) | TSHRNPSR1ALOX15MEN1KMT2A | |
| SCHEMBL2081210 | 0.86 | NPC1 (0.43) | TSHRVNN1ALDH1A1SRD5A2 | |
| SCHEMBL1643403 | 0.85 | NT5E (0.47) | TSHRNPSR1VNN1MEN1KMT2A | |
| SCHEMBL1643182 | 0.83 | KDM4C (0.56) | TSHRNPSR1MEN1KMT2A | |
| SCHEMBL5742098 | 0.81 | TACR1 (0.55) | RXFP1 | |
| SCHEMBL2079912 | 0.77 | VNN1 (0.51) | TSHRNPSR1ALOX15CASP1HSD17B10 | |
| SCHEMBL2076801 | 0.76 | ALDH1A1 (0.66) | TSHRNPSR1ALOX15CASP1HSD17B10 | |
| SCHEMBL1643097 | 0.73 | TSHR (0.41) | TSHRHSD17B10KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL1644026 | 0.72 | TSHR (0.51) | TSHRVNN1MEN1KMT2AALDH1A1 | |
| SCHEMBL1643694 | 0.72 | HPGD (0.40) | TSHRALOX15MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | disclosed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | disclosed |
| CN-101501034-A | 1, 7-naphthyridine derivatives as inhibitors of p38 mitogen-activated protein kinase | ALMIRALL LAB (ES) | 2009-08-05 | — | — | CN | disclosed |
| EP-2049537-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017461-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | TSHR 4026/4885NPSR1 3360/4885ALOX15 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.